Iovance Biotherapeutics, Inc. Common Stock (IOVA) is a publicly traded Healthcare sector company. As of May 21, 2026, IOVA trades at $3.54 with a market cap of $1.51B and a P/E ratio of -1.86. IOVA moved +2.02% today. Year to date, IOVA is +44.49%; over the trailing twelve months it is +85.34%. Its 52-week range spans $1.64 to $12.51. Analyst consensus is buy with an average price target of $8.44. Rallies surfaces IOVA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Iovance Biotherapeutics Narrows Q1 Loss to $0.19, Misses Revenue Estimates: Iovance Biotherapeutics posted a Q1 loss of $0.19 per share, narrowing from a $0.36 loss a year ago. Quarterly revenue missed analysts' consensus estimates.
| Metric | Value |
|---|---|
| Price | $3.54 |
| Market Cap | $1.51B |
| P/E Ratio | -1.86 |
| EPS | $-1.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.51 |
| 52-Week Low | $1.64 |
| Volume | 21 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.19M |
| Net Income | $-444.04M |
| Gross Margin | -804.54% |
10 analysts cover IOVA: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.44.